ArticleJournal of neurosurgery. Case lessons2025
Functional hemispherectomy for seizure control in encephalocraniocutaneous lipomatosis: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEncephalocraniocutaneous lipomatosis (ECCL) is a rare neurocutaneous syndrome composed of a spectrum of congenital cutaneous, ocular, and brain anomalies. Principal anomalies include nevus psiloliparus lesions of the scalp, ocular choristomas consisting of dermolipomas, and intracranial lipomas and arachnoid cysts. The hypothesized pathogenic basis in ECCL is a developmental mesenchymal defect involving neural crest cell derivatives. Management is typically focused on treating symptoms, directed at the organ system and supportive neurorehabilitation. Reports to date have only focused on pharmacotherapeutic treatment of drug-refractory epilepsy (DRE), a principal neurological phenotype. Surgical management of medication-refractory epilepsy, which can occur in up to 70% of ECCL subjects, has not been described to date. OBSERVATIONS: The authors present an illustrative case report of a 4-year-old girl with ECCL who developed DRE and underwent a functional hemispherectomy for seizure relief. The clinical course, diagnostic evaluation, and surgical treatment are described, with emphasis on surgical-pathological observations. LESSONS: To the authors' knowledge, surgical treatment for hemispheric onset DRE in the context of ECCL has not been reported. Systemic and clinical features on presentation are reviewed to highlight aberrant mesenchymal differentiation as the developmental basis for the syndrome. The authors also underscore the role of functional hemispherectomy in the treatment of DRE in the context of a genetic/developmental syndrome. https://thejns.org/doi/10.3171/CASE2578.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.